Inspire Medical prices up-sized $108m IPO

Inspire Medical Systems yesterday up-sized its initial public offering to $108 million, or some $124 million if the underwriters option is exercised in full. Maple Grove, Minn.-based Inspire, which spun out from Medtronic (NYSE:MDT) in 2007, makes devices for treating obstructive sleep apnea. The company had said it planned to issue 5 million shares at $14 to $16 apiece, which would have fetched $75 million at the midpoint. But in a regulatory filing yesterday, Inspire said it sold 6.75 million shares at $16 apiece and put an underwriters option on the table that’s worth another $16.2 million. Inspire, which posted net losses of -$17.5 million on sales of $28.6 million last year, plans to list on the New York Stock Exchange under the INSP symbol. The flotation is slated to price next week. The company developed a pacemaker-like system designed to stimulate nerves to keep airways open during sleep to treat obstructive sleep apnea. BofA Merrill Lynch and Goldman Sachs &Co are acting as underwriters for the offering, according to an SEC filing. In November 2016, Inspire Medical closed a $37.5 million Series F round. The post Inspire Medical prices up-sized $108m IPO appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Funding Roundup Initial Public Offering (IPO) Neuromodulation/Neurostimulation Respiratory Wall Street Beat Inspire Medical Systems Inc. Source Type: news

Related Links:

ConclusionNAFLD is an additional risk factor in OSA subject which contributes to systemic inflammation in Asian Indians.
Source: Sleep and Breathing - Category: Respiratory Medicine Source Type: research
Authors: Keshavarzi F, Mehdizadeh S, Khazaie H, Ghadami MR Abstract OBJECTIVE: Obstructive sleep apnea (OSA) is a risk factor for adverse pregnancy outcomes. The aim of this study was to evaluate the association between OSA and preeclampsia. METHODS: Between 30 and 39 weeks gestation, objective sleep apnea were evaluated in 38 normal pregnant and 40 preeclamptic women. Preeclampsia was defined by having a blood pressure (BP)> 140/90 mmHg on two occasions after the 20th week of pregnancy with excess protein in the urine (> 300 mg in 24 h) or 30 mg persistent proteinuria (...
Source: Hypertension in Pregnancy - Category: OBGYN Tags: Hypertens Pregnancy Source Type: research
Authors: Zhang L, Wu Q, Zhang Q, Lu G, Yuan Y, Wang T PMID: 30021417 [PubMed - as supplied by publisher]
Source: Panminerva Medica - Category: General Medicine Tags: Panminerva Med Source Type: research
This study aims to use methods of scoring collaterals on CT angiography to analyze changes in collateral circulation in untreated patients with moderate and severe OSAS before and after nasal continuous positive airway pressure (CPAP) treatment. PATIENTS AND METHODS: Ninety-eight moderate and severe OSAS patients treated with nasal CPAP and seventy-four controls that weren't treated with CPAP, were involved in this study. Two independent neuroradiologists evaluated intracranial collaterals by using Miteff scale, modified Tan scale. Intracranial collaterals differences were compared between OSAS group (before and after ...
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
The objective of the study was to evaluate the relative prevalence of cardiovascular as well as other comorbidities, in patients with the overlap syndrome, as compared to patients that are diagnosed solely with OSA. PATIENTS AND METHODS: We examined thirty-eight (38) patients (27 men, 11 women) with coexisting COPD and OSA - overlap syndrome (Group 1) vs. 38 patients with OSA-only (Group 2), matched for sex, age, and Body Mass Index (BMI). All patients underwent pulmonary function tests (PFTs), oximetry and overnight polysomnography and were asked about other coexisting chronic diseases and medications. RESULTS: Th...
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
(American Thoracic Society) Supplemental oxygen eliminates the rise in morning blood pressure experienced by obstructive sleep apnea (OSA) patients who stop using continuous positive airway pressure (CPAP), the standard treatment for OSA, according to new research published online in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
ConclusionsSuccessful treatment of OSA with MAD can restore LTL and SIRT1 protein levels in PBMC.Clinical relevanceLTL and SIRT1 protein levels in PBMC can be improved following effective treatment of OSA using MAD.
Source: Clinical Oral Investigations - Category: Dentistry Source Type: research
In this study, we examined the impact of OSA on the employment of soldiers on continuous positive airways pressure (CPAP) therapy by measuring several items: work absenteeism using the Work Productivity and Activity Impairment (WPAI) questionnaire, diurnal hypersomnia, and career advancement. METHODS: A questionnaire was sent by regular mail to 940 soldiers with OSA on CPAP therapy who are insured by the French Military Healthcare Fund (Caisse Nationale Militaire de Sécurité Sociale). RESULTS: Questionnaires were returned by 439 soldiers: mean age 47 years; mean body mass index 29.8kg/m2. Absenteeism ...
Source: Revue d Epidemiologie et de Sante Publique - Category: Epidemiology Tags: Rev Epidemiol Sante Publique Source Type: research
Conclusions: The confounding factors present in the triad of OSAS, COPD, and obesity prevented the perception of increased daytime sleepiness and high risk for OSAS. We observed no worsening of dyspnea perception or quality of life.RESUMO Objetivo: Avaliar se a presen ça de síndrome da apneia obstrutiva do sono (SAOS) modifica a percepção de queixas respiratórias e de qualidade de vida em pacientes com DPOC por meio de questionários específicos, além de verificar se escalas de sonolência diurna e de rastreamento para SAOS podem ser empregadas na tríade SA...
Source: Jornal Brasileiro de Pneumologia - Category: Respiratory Medicine Source Type: research
Condition:   Obstructive Sleep Apnea Intervention:   Other: CSR remote monitoring Sponsors:   Groupe Medical de Pneumologie, Polyclinique Saint-Laurent;   Slb Pharma;   Vitalaire;   Agence Régionale de Santé - Bretagne;   ResMed Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Brain | Funding | Neurology | Obstructive Sleep Apnea | Respiratory Medicine | Sleep Apnea | Sleep Disorders | Sleep Medicine